In recent years, several states have implemented policies in the commercial fully-insured market that attempt to limit patient out-of-pocket (OOP) expenses for pharmacy benefits. This report examines key considerations for states, payers and patients for a range of policies, including the potential impact on member premiums and OOP costs for patients that rely on specialty drugs.
This article was commissioned by Bristol Myers Squibb.